Starling Oncology Reports Q3 Results and Updates 2026 Guidance
Specialty pharmacy revenue was $109 million, up 44% year over year, with a 24% gross margin. The company also updated its full-year 2026 guidance.
Starling Oncology, Inc. (NASDAQ: STLN) announced its financial results for the third quarter ended September 30, 2026, alongside an update to its full-year 2026 guidance. The company reported specialty pharmacy revenue of $109 million, representing a 44 percent increase year over year, with a gross margin of 24 percent. As a value-based community oncology practice, the company continues to integrate clinical trials, transfusions, and specialty pharmacy services into its care model.
The report reflects the company's ongoing efforts to coordinate cancer care across its network of over 100 clinics and 400 clinicians.